Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint

Molecular and Cellular Biology

Volumn 32, Issue 2, 2012, Pages 348-364

  Miceli, Alexander P ^a,b   Saporita, Anthony J ^a,b   Weber, Jason D ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; DENTIN MATRIX PROTEIN 1; MTORC1 PROTEIN; PROTEIN P53; RAS PROTEIN; TSC1 PROTEIN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE CHECKPOINT; FEMALE; GENE DELETION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSLATION INITIATION;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, NUDE; NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84856800924     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06030-11     Document Type: Article

References (55)

1. Apicelli AJ, et al. 2008. A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol. Cell. Biol. 28: 1068-1080.
2. Azzam ME, Algranati ID. 1973. Mechanism of puromycin action: fate of ribosomes after release of nascent protein chains from polysomes. Proc. Natl. Acad. Sci. U. S. A. 70:3866-3869.
3. Bates S, et al. 1998. p14ARF links the tumour suppressors RB and p53. Nature 395:124-125.
4. Brady SN, Yu Y, Maggi LB, Jr,Weber JD. 2004. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 24:9327-9338.
5. Chen J, Kastan MB. 2010. 5=-3=-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev. 24:2146-2156.
6. Crino PB, Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. New Engl. J. Med. 355:1345-1356.
7. Dai Y, Grant S. 2010. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16:376-383.
8. de Stanchina E, et al. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12:2434-2442.
9. Elledge SJ. 1996. Cell cycle checkpoints: preventing an identity crisis. Science 274:1664-1672.
10. Grech G, et al. 2008. Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting ery-throid differentiation. Blood 112:2750-2760.
11. Guertin DA, Sabatini DM. 2007. Dening the role of mTOR in cancer. Cancer Cell 12:9-22.
12. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
13. Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes Dev. 18:1926-1945.
14. Inoki K, Corradetti MN, Guan KL. 2005. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37:19-24.
15. Inoki K, Guan KL. 2009. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum. Mol. Genet. 18: R94-100.
16. Inoue K, Mallakin A, Frazier DP. 2007. Dmp1 and tumor suppression. Oncogene 26:4329-4335.
17. Inoue K, Roussel MF, Sherr CJ. 1999. Induction of ARF tumor suppres-sor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl. Acad. Sci. U. S. A. 96:3993-3998.
18. Inoue K, et al. 2000. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumori-genesis. Genes Dev. 14:1797-1809.
19. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. 2001. Dmp1 is haplo-insufcient for tumor suppression and modies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 15: 2934-2939.
20. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. 1999. Tumor spectrum in ARF-decient mice. Cancer Res. 59:2217-2222.
21. Kamijo T, et al. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
22. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.
23. Kladney RD, et al. 2010. Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice. Cancer Res. 70:8937-8947.
24. Knaup KX, et al. 2009.Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability.Mol. Cancer Res. 7:88-98.
25. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. 2004. N-terminal polyubiquitination and degradation of theArf tumor suppressor. Genes Dev. 18:1862-1874.
26. Kwiatkowski DJ, et al. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:525-534.
27. Lee CH, et al. 2007. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBOJ. 26:4812-4823.
28. -ΔΔCT method. Methods 25: 402-408.
29. Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10:307-318.
30. Mills JR, et al. 2008. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. U. S. A. 105:10853-10858.
31. Olanich ME, Moss BL, Piwnica-Worms D, Townsend RR, Weber JD. 2011. Identication of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene 30: 77-86.
32. Palmero I, Pantoja C, Serrano M. 1998. p19ARF links the tumour sup-pressor p53 to Ras. Nature 395:125-126.
33. Pelletier CL, et al. 2007. TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. Cancer Res. 67:1609-1617.
34. Proud CG. 2007. Signalling to translation: how signal transduction path-ways control the protein synthetic machinery. Biochem. J. 403:217-234.
35. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated pro-teins capable of inducing cell cycle arrest. Cell 83:993-1000.
36. Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N. 1998. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. U. S. A. 95: 13194-13199.
37. Roussel MF, Theodoras AM, Pagano M, Sherr CJ. 1995. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl. Acad. Sci. U. S. A. 92:6837-6841.
38. Saporita AJ, Maggi LB Jr, Apicelli AJ, Weber JD. 2007. Therapeutic targets in the ARF tumor suppressor pathway. Curr. Med. Chem. 14: 1815-1827.
39. Shaw RJ, Cantley LC. 2006. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430.
40. Sherr CJ. 2006. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6:663-673.
41. Spriggs KA, Bushell M,Willis AE. 2010. Translational regulation of gene expression during conditions of cell stress. Mol. Cell 40:228-237.
42. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. 2005. Ras-Raf-Arf signaling critically depends on theDmp1 transcription factor. Mol. Cell. Biol. 25:220-232.
43. Stefani G, Fraser CE, Darnell JC, Darnell RB. 2004. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J. Neurosci. 24:7272-7276.
44. Strezoska Z, Pestov DG, Lau LF. 2000. Bop1 is a mouse WD40 repeat nucleolar protein involved in 28S and 5.8S RRNA processing and 60S ribosome biogenesis. Mol. Cell. Biol. 20:5516-5528.
45. TakagiM, AbsalonMJ,McLure KG, KastanMB. 2005. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123:49-63.
46. Tee AR, et al. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U. S. A. 99: 13571-13576.
47. Thermann R, Hentze MW. 2007. Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. Nature 447:875-878.
48. Volanakis EJ, Sherr CJ. 2010. Developmental strategies for evasion of Arf tumor suppression. Cell Cycle 9:14-15.
49. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. 2003. Ras modulatesMyc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3:219-231.
50. Weber JD, et al. 2000. Cooperative signals governing ARF-mdm2 inter-action and nucleolar localization of the complex. Mol. Cell. Biol. 20: 2517-2528.
51. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:20-26.
52. Weber RG, et al. 2007. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 26:1088-1097.
53. Zhang H, et al. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112:1223-1233.
54. Zindy F, et al. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
55. Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev.Mol. Cell Biol. 12:21-35.